title: Treating maculopathy at the expense of proliferative disease: an emerging problem in 'macular treatment centres'.
authors: Department of Ophthalmology, St James's University Hospital, Leeds, UK.
authors: M A
authors: MA
authors: Mookhtiar
authors: Department of Ophthalmology, St James's University Hospital, Leeds, UK.
authors: Z I
authors: ZI
authors: Carrim
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D003922:Diabetes Mellitus, Type 1 / Q000150:complications; D003930:Diabetic Retinopathy / Q000188:drug therapy*; D006801:Humans; D058449:Intravitreal Injections; D017075:Laser Coagulation; D008269:Macular Edema / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications; D000069579:Ranibizumab; D015861:Retinal Neovascularization / Q000175:diagnosis* / Q000601:surgery; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000069579:Ranibizumab